- Conditions
- COVID-19, Pharmacokinetics, Safety
- Interventions
- Q-Griffithsin, Placebo
- Drug
- Lead sponsor
- Sharon Hillier
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurotrophic Keratitis
- Interventions
- CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
- Biological
- Lead sponsor
- Claris Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 45
- States / cities
- Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more
- Conditions
- Onychomycosis
- Interventions
- ME1111 Solution, Low strength, ME1111 Solution, High strength, Matching Vehicle Solution
- Drug
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Encinitas, California • San Diego, California + 28 more
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
- Conditions
- oGVHD, Ocular Graft Versus Host Disease
- Interventions
- d-MAPPS™ Ophthalmic Solution, Matching vehicle control
- Biological
- Lead sponsor
- Regenerative Ocular Immunobiologics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Palm Harbor, Florida • Boston, Massachusetts
- Conditions
- Primary Open-angle Glaucoma (POAG), Ocular Hypertension
- Interventions
- SHP639 (n=60), Placebo Comparator (n=24)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Paroxysmal Atrial Fibrillation
- Interventions
- FlecIH-103
- Drug
- Lead sponsor
- InCarda Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 18
- States / cities
- Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more
- Conditions
- Dry Eye Disease, Dry Eye Syndrome
- Interventions
- AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more
- Conditions
- Ocular Hypertension, Primary Open Angle Glaucoma
- Interventions
- AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- Aerpio Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Austin, Texas • Dallas, Texas
- Conditions
- Healthy
- Interventions
- JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona